<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Unity Biotechnology Approves Company Liquidation Plan

PremiumCompany Announcements

1M ago

UBX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

3M ago

Unity Biotechnology Alters Voting Dynamics with New Stock

PremiumCompany Announcements

3M ago

Four new option listings and three option delistings on July 9th

PremiumThe Fly

4M ago

ECG

EMA

PremiumCompany AnnouncementsUnity Biotechnology Faces Nasdaq Delisting and Leadership Changes

4M ago

Unity Biotechnology Faces Nasdaq Delisting Notice

Company Announcements

Unity Biotechnology Faces Nasdaq Delisting Notice

4M ago

Unity Biotechnology: Hold Rating Amid Leadership Changes and Mixed UBX1325 Study Results

Ratings

Unity Biotechnology: Hold Rating Amid Leadership Changes and Mixed UBX1325 Study Results

5M ago

Unity Biotechnology downgraded to Neutral from Buy at H.C. Wainwright

PremiumThe Fly

5M ago

Unity Biotechnology downgraded to Neutral from Outperform at Mizuho

PremiumThe Fly

5M ago

Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study

PremiumCompany Announcements

6M ago

Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE

PremiumThe Fly

6M ago

PremiumCompany AnnouncementsUnity Biotechnology Reports Q1 2025 Financials and Study Updates

6M ago

Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study

The Fly

Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study

6M ago

Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment

Ratings

Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment

6M ago

Unity Biotechnology reports Q1 EPS (43c), consensus (40c)

PremiumThe Fly

6M ago

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

PremiumThe Fly

7M ago

Unity Biotechnology price target lowered to $4 from $6 at Chardan

PremiumThe Fly

7M ago

Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study

PremiumRatings

7M ago

PremiumThe FlyUnity Biotechnology announces results from ASPIRE Phase 2b study in DME

7M ago

Unity Biotechnology Appoints Dr. Yehia Hashad to Board

Company Announcements

Unity Biotechnology Appoints Dr. Yehia Hashad to Board

8M ago

Unity Biotechnology appoints Hashad to board of directors

The Fly

Unity Biotechnology appoints Hashad to board of directors

8M ago